Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 2
2010 5
2011 3
2012 6
2013 3
2014 2
2015 11
2016 4
2017 9
2018 8
2019 2
2020 5
2021 3
2022 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

57 results

Results by year

Filters applied: . Clear all
Page 1
Longitudinal Comparative Analysis of Circulating Tumor DNA and Matched Tumor Tissue DNA in Patients with Metastatic Colorectal Cancer Receiving Palliative First-Line Systemic Anti-Cancer Therapy.
Lee SB, Kim JW, Kim HG, Hwang SH, Kim KJ, Lee JH, Seo J, Kang M, Jung EH, Suh KJ, Kim SH, Kim JW, Kim YJ, Kim JH, Kwon NJ, Lee KW. Lee SB, et al. Among authors: kim kj. Cancer Res Treat. 2024 Apr 29. doi: 10.4143/crt.2024.016. Online ahead of print. Cancer Res Treat. 2024. PMID: 38697850
Amphiregulin can predict treatment resistance to palliative first-line cetuximab plus FOLFIRI chemotherapy in patients with RAS wild-type metastatic colorectal cancer.
Kim SA, Park H, Kim KJ, Kim JW, Sung JH, Nam M, Lee JH, Jung EH, Suh KJ, Lee JY, Kim SH, Lee JO, Kim JW, Kim YJ, Kim JH, Bang SM, Lee JS, Lee KW. Kim SA, et al. Among authors: kim kj. Sci Rep. 2021 Dec 10;11(1):23803. doi: 10.1038/s41598-021-03197-9. Sci Rep. 2021. PMID: 34893673 Free PMC article.
Cetuximab resistance induced by hepatocyte growth factor is overcome by MET inhibition in KRAS, NRAS, and BRAF wild-type colorectal cancers.
Kim SA, Park H, Kim KJ, Kim JW, Sung JH, Nam M, Lee JH, Jung EH, Suh KJ, Lee JY, Kim SH, Lee JO, Kim JW, Kim YJ, Kim JH, Bang SM, Lee JS, Lee KW. Kim SA, et al. Among authors: kim kj. J Cancer Res Clin Oncol. 2022 Nov;148(11):2995-3005. doi: 10.1007/s00432-021-03872-4. Epub 2021 Dec 1. J Cancer Res Clin Oncol. 2022. PMID: 34853888
57 results